Treating high-risk bladder cancer after surgery
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs (sacituzumab govitecan and nivolumab) given after surgery to prevent the return of muscle-invasive bladder cancer. It is for patients whose cancer has a high chance of coming back despite surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You had surgery to remove your bladder or kidney and ureter within the last 6 months.
- Your cancer was muscle-invasive and came from the bladder, ureter, or kidney pelvis.
- You have no signs of cancer on scans after surgery.
- You are in generally good health (able to care for yourself) and your blood counts and organ function meet study levels.
- You have not previously received immunotherapy (PD-1/PD-L1 inhibitors) or the drug sacituzumab govitecan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new immunotherapy drug called sasanlimab as a maintenance treatment after chemotherapy and bladder removal surgery. The goal is to see if it helps keep the cancer from coming back in people with muscle-invasive bladder cancer.
This trial tests a new drug called sacituzumab tirumotecan for people with low-grade bladder cancer that hasn't spread into the bladder muscle. The goal is to see if it can help shrink or control the tumors.
This Phase 1 study tests whether a new bladder-cancer treatment plan—radiation given at the same time as sacituzumab govitecan—can help people with muscle-invasive bladder cancer without starting with traditional chemo/radiation. Because it’s early-stage, the main goal is safety and learning the best way to use this combination to preserve the bladder.
This trial tests a combination of two drugs—one that targets cancer cells directly and another that helps your immune system fight the cancer—to try to get rid of the cancer without needing to remove your bladder. If you have muscle-invasive bladder cancer and are unable or unwilling to have bladder removal surgery, this approach might be an option for you.
This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.
This trial is testing a drug called sacituzumab govitecan, sometimes combined with atezolizumab (an immunotherapy), for rare cancers of the bladder, urinary tract, kidney, or penis. The goal is to see if these treatments work well for people whose cancers have not responded to other options.
Hear when a new Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.